35 results about "Poly(glycerol-sebacate)" patented technology

A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores.

A composite lumen includes an extruded tube of a composite including a poly(glycerol sebacate) (PGS) matrix mixed with a PGS thermoset filler. The composite lumen also includes an overbraid structure overlying an outer surface of the extruded tube. A method of forming a composite lumen includes extruding a PGS tube of a composite including a PGS matrix mixed with a PGS thermoset filler. The method also includes applying an overbraid structure over an outer surface of the extruded tube.

A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w / w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).

A bone filling composition includes a bone filler. The bone filler includes microparticles of at least one elastomeric material. The at least one elastomeric material includes a poly(glycerol sebacate)-based thermoset. The poly(glycerol sebacate)-based thermoset may be porous thermoset poly(glycerol sebacate) flour, thermoset poly(glycerol sebacate) microspheres, or a combination thereof. In some embodiments, the bone filling composition is a bone filling composite that further includes a carrier material including a poly(glycerol sebacate) resin. A method of forming a bone filling composite includes selecting a bone filler and mixing the bone filler with a carrier material to form the bone filling composite. A method of treating a bony defect includes molding a bone filling composite and placing the bone filling composite in the bony defect. The bone filling composite includes a bone filler mixed with a carrier material.

The invention provides a degradable shape memory polymer, its preparation method and application, and a 4D printed degradable inferior vena cava filter, belonging to the technical field of implantable medical devices. In the shape memory polymer provided by the present invention, the structural part of polyglycerol sebacate has an aliphatic long carbon chain structure, which can provide good biocompatibility, biodegradability and good cell binding performance; hydroxyethyl methacrylate The structural part provides the mechanical support required for the inferior vena cava filter; the acrylating group makes the composite material photocurable. The present invention uses the above-mentioned shape memory polymer and combines 3D printing technology to prepare a 4D printed degradable inferior vena cava filter, which is not only biodegradable, but also has good biocompatibility and ensures long-term patency of blood vessels; and has excellent mechanical properties and Deformability, can effectively intercept blood clots in a short period of time.

The invention discloses an isocyanate-crosslinked polyethylene glycol-polyglyceryl sebacate bioelastomer, a preparation method and application thereof. The bioelastomer structure of the present invention is shown in formula I, wherein n is an integer of 10-80; m is an integer of 2-14. The bioelastomer of the present invention, whose mechanical strength, hydrophilicity and hydrophobicity, degradation behavior, cell behavior and biocompatibility can be regulated and optimized through the content of isocyanate and polyethylene glycol, is a soft tissue repair with great clinical application prospects Material.

Anesthetics covalently conjugated onto biodegradable and biocompatible hydrophilic polymers via hydrolysable linkages provide controlled release of local anesthetics in vivo in an effective amount fornerve blockade with reduced toxicity relative to the unconjugated anesthetic agent. The rate of anesthetic release can be tuned by changing the hydrophilicity of the polymer. Exemplary formulations of Poly (glycerol sebacate) (PGS), optionally including Poly ethylene glycol (PEG) polymers conjugated to Tetrodotoxin (TTX) (PGS-PEG-TTX and PGS-TTX), and methods of use thereof are provided Nerve blockade from PGS-PEG-TTX and PGS-TTX was associated with minimal systemic and local toxicity to the muscle and the peripheral nerves. TDP-TTX conjugates homogeneously dispersed into PEG200 are also described. PEG200 not only worked as a medium, but also worked as a chemical permeation enhancer (CPE) to enhance the effectiveness of TTX.

A biocontainment vessel includes a vessel structure including a structural composition and an enhancement composition associated with the structural composition. The enhancement composition includes a co-polymer. The co-polymer is a poly(glycerol sebacate) or a poly(glycerol sebacate urethane). The enhancement composition may also include an augmentation agent associated with the co-polymer. The enhancement composition is located with respect to the structural composition such that the enhancement composition benefits biological cells contained in the biocontainment vessel. A composition includes a co-polymer and an augmentation agent contained by the co-polymer. A method of containing biological cells includes placing the biological cells in an augmented biocontainment vessel and storing them in the augmented biocontainment vessel under predetermined conditions. An augmented substrate includes a substrate and an enhancement composition coating a surface of the substrate.

Cardiovascular prostheses having particulate structures that are adapted to induce modulated healing of damaged or diseased cardiovascular tissue and, thereby, associated structures, when administered thereto. The particulate structures include a biological component and a polymer component. The biological component is in the form of a composition and includes decellularized amniotic membrane and placental tissue. The biological composition can also include a plurality of exosomes derived from mesenchymal stem cells or embryonic stem cells. The polymer component includes poly(glycerol sebacate) (PGS).

The invention discloses a mesoporous bioactive glass / poly-decyl diacid glyceride composite support as well as a preparation method and an application thereof. The composite support of the invention uses a mesoporous bioactive glass porous support as a matrix and compounds poly-decyl diacid glyceride on the mesoporous bioactive glass porous support. Mechanical strength, degradation rate, drug release rate, cell behavior and the like of the composite support of the invention can be adjusted by pore wall thickness of the mesoporous bioactive glass matrix and thickness of the poly-decyl diacid glyceride coating. A PGS coating is utilized to successfully solve the problem of brittleness of an MBG support, so that mechanical strength of the composite support is adjustable in a load bearing range of a trabecular bone. According to the invention, adjustment to degradation rate and release rate of proteins immobilized in MBG mesopore can be realized and activities of the immobilized proteins free of influence from a moderate coating operation can be realized; and cell experiments prove that the PGS coating is capable of promoting cell adhesion and proliferation on surface of the support without affecting osteogenic activity of the MBG.

Prostheses are described for stabilizing dysfunctional sacroiliac (SI) joints. The prostheses are sized and configured to be press-fit into surgically created pilot SI joint openings in dysfunctional SI joint structures. The prostheses include a polymer composition comprising poly (glycerol sebacate) (PGS). The polymer composition can also include selective biologically active agents, such as a bone morphogenic protein (BMP), and / or a pharmacological agent, such as an antibiotic.

The invention relates to glabridin micro-emulsion and a preparation method thereof. The glabridin micro-emulsion consists of the following components in percentage by weight: 10wt%-15wt% of glabridin, 10wt%-15wt% of stearic polyoxypropylene sulfite, 7wt%-11wt% of polydecyldiacid glyceride, 6wt%-9wt% of Twain 85, 12wt%-16wt% of propylene glycol and the balance of deionized water. The preparation method of the glabridin micro-emulsion comprises the steps of mixing and vortex oscillation, and the prepared glabridin micro-emulsion is high in encapsulation efficiency, good in stability and capable of being added into cosmetics as an ingredient for improving the stability of the glabridin.

A manufacturing process includes spinning at least one continuous poly(glycerol sebacate) (PGS) / alginate fiber from a polymeric solution comprising PGS and alginate in water, drafting the at least one continuous PGS / alginate fiber in at least one coagulation bath, and drawing the at least one continuous PGS / alginate fiber from the at least one coagulation bath. A yarn includes at least one continuous PGS fiber. A continuous poly(glycerol sebacate) (PGS) / alginate fiber forming system includes a feeding tank holding a polymeric solution of alginate and PGS, a pump, a spinneret, a first coagulation bath, a first winder, a second coagulation bath, a second winder, and a bobbin winder, the system forming at least one continuous PGS / alginate fiber from the polymeric solution of alginate and PGS.